{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:17:20Z","timestamp":1788308240657,"version":"build-2803163510"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"16","license":[{"start":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T00:00:00Z","timestamp":1692748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T00:00:00Z","timestamp":1692748800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"the National Youth Science Foundation of China","award":["No. 82002783"],"award-info":[{"award-number":["No. 82002783"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2023,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>Immunotherapy is an attractive treatment for breast cancer. Cancer-testis antigens (CTAs) are potential targets for immunotherapy for their restricted expression. Here, we investigate the expression of CTAs in breast cancer and their value for prognosis. So as to hunt for a potential panel of CTAs for universal immunotherapeutic targets.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Material and methods<\/jats:title>\n                <jats:p>A total of 137 breast cancer tissue specimens including 51 triple-negative breast cancer (TNBC) were assessed for MAGE-A4, MAGEA1, NY-ESO-1, KK-LC-1 and PRAME expression by immunohistochemistry. The expression of PD-L1 and TILs was also calculated and correlated with the five CTAs. Clinical data were collected to evaluate the CTA\u2019s value for prognosis. Data from the K-M plotter were used as a validation cohort.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The expression of MAGE-A4, NY-ESO-1 and KK-LC-1 in TNBC was significantly higher than in non-TNBC (<jats:italic>P<\/jats:italic>\u2009=\u20090.012, <jats:italic>P<\/jats:italic>\u2009=\u20090.005, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001 respectively). 76.47% of TNBC expressed at least one of the five CTAs. Patients with positive expression of either MAGE-A4 or PRAME had a significantly extended disease-free survival (DFS). Data from the Kaplan\u2013Meier plotter confirm our findings.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>MAGE-A4, NY-ESO-1, PRAME and KK-LC-1 are overexpressed in breast cancer, especially in TNBC. Positive expression of MAGE-A4 or PARME may be associated with prolonged DFS. A panel of CTAs is attractive universal targets for immunotherapy.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00432-023-05274-0","type":"journal-article","created":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T09:28:19Z","timestamp":1692782899000},"page":"15003-15011","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Expression of four cancer-testis antigens in TNBC indicating potential universal immunotherapeutic targets"],"prefix":"10.1007","volume":"149","author":[{"given":"Jie","family":"Xiao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengli","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lianru","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baorui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,23]]},"reference":[{"key":"5274_CR1","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1007\/s00262-011-1005-7","volume":"60","author":"S Adams","year":"2011","unstructured":"Adams S, Greeder L, Reich E, Shao Y, Fosina D et al (2011) Expression of cancer testis antigens in human BRCA-associated breast cancers: potential targets for immunoprevention? Cancer Immunol Immunother 60:999\u20131007","journal-title":"Cancer Immunol Immunother"},{"key":"5274_CR2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0038783","volume":"7","author":"FO Ademuyiwa","year":"2012","unstructured":"Ademuyiwa FO, Bshara W, Attwood K, Morrison C, Edge SB et al (2012) NY-ESO-1 cancer testis antigen demonstrates high immunogenicity in triple negative breast cancer. PLoS ONE 7:e38783","journal-title":"PLoS ONE"},{"key":"5274_CR3","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1038\/s41379-021-00823-9","volume":"34","author":"S Ahn","year":"2021","unstructured":"Ahn S, Kim KM (2021) PD-L1 expression in gastric cancer: interchangeability of 22C3 and 28\u20138 pharmDx assays for responses to immunotherapy. Mod Pathol 34:1719\u20131727","journal-title":"Mod Pathol"},{"issue":"12","key":"5274_CR4","doi-asserted-by":"publisher","first-page":"3612","DOI":"10.3390\/cancers12123612","volume":"12","author":"M Albertsmeier","year":"2020","unstructured":"Albertsmeier M, Altendorf-Hofmann A, Lindner LH, Issels RD, Kampmann E et al (2020) Cancer testis antigens and immunotherapy: expression of PRAME is associated with prognosis in soft tissue sarcoma. Cancers (basel) 12(12):3612","journal-title":"Cancers (basel)"},{"key":"5274_CR5","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1186\/1471-2407-13-271","volume":"13","author":"D Balafoutas","year":"2013","unstructured":"Balafoutas D, zur Hausen A, Mayer S, Hirschfeld M, Jaeger M et al (2013) Cancer testis antigens and NY-BR-1 expression in primary breast cancer: prognostic and therapeutic implications. BMC Cancer 13:271","journal-title":"BMC Cancer"},{"key":"5274_CR6","first-page":"32","volume":"47","author":"D Bandi\u0107","year":"2006","unstructured":"Bandi\u0107 D, Jureti\u0107 A, Sarcevi\u0107 B, Separovi\u0107 V, Kujundzi\u0107-Tiljak M et al (2006) Expression and possible prognostic role of MAGE-A4, NY-ESO-1, and HER-2 antigens in women with relapsing invasive ductal breast cancer: retrospective immunohistochemical study. Croat Med J 47:32\u201341","journal-title":"Croat Med J"},{"key":"5274_CR7","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.semcancer.2019.10.023","volume":"72","author":"M Benvenuto","year":"2021","unstructured":"Benvenuto M, Focaccetti C, Izzi V, Masuelli L, Modesti A et al (2021) Tumor antigens heterogeneity and immune response-targeting neoantigens in breast cancer. Semin Cancer Biol 72:65\u201375","journal-title":"Semin Cancer Biol"},{"key":"5274_CR8","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.ygyno.2016.08.325","volume":"143","author":"RM Brightwell","year":"2016","unstructured":"Brightwell RM, Grzankowski KS, Lele S, Eng K, Arshad M et al (2016) The CD47 \u201cdon\u2019t eat me signal\u201d is highly expressed in human ovarian cancer. Gynecol Oncol 143:393\u2013397","journal-title":"Gynecol Oncol"},{"key":"5274_CR9","doi-asserted-by":"publisher","first-page":"12172","DOI":"10.1038\/s41598-021-91290-4","volume":"11","author":"C Chen","year":"2021","unstructured":"Chen C, Gao D, Huo J, Qu R, Guo Y et al (2021) Multiomics analysis reveals CT83 is the most specific gene for triple negative breast cancer and its hypomethylation is oncogenic in breast cancer. Sci Rep 11:12172","journal-title":"Sci Rep"},{"key":"5274_CR10","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.breast.2019.12.002","volume":"49","author":"G Curigliano","year":"2020","unstructured":"Curigliano G, Bagnardi V, Ghioni M, Louahed J, Brichard V et al (2020) Expression of tumor-associated antigens in breast cancer subtypes. Breast 49:202\u2013209","journal-title":"Breast"},{"key":"5274_CR11","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.cytogfr.2017.06.011","volume":"36","author":"F Dammeijer","year":"2017","unstructured":"Dammeijer F, Lau SP, van Eijck CHJ, van der Burg SH, Aerts J (2017) Rationally combining immunotherapies to improve efficacy of immune checkpoint blockade in solid tumors. Cytokine Growth Factor Rev 36:5\u201315","journal-title":"Cytokine Growth Factor Rev"},{"key":"5274_CR12","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1158\/2159-8290.CD-17-1417","volume":"8","author":"SP D'Angelo","year":"2018","unstructured":"D\u2019Angelo SP, Melchiori L, Merchant MS, Bernstein D, Glod J et al (2018) Antitumor activity associated with prolonged persistence of adoptively transferred NY-ESO-1 (c259)T cells in synovial sarcoma. Cancer Discov 8:944\u2013957","journal-title":"Cancer Discov"},{"key":"5274_CR13","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s40425-017-0295-5","volume":"5","author":"PM Dillon","year":"2017","unstructured":"Dillon PM, Petroni GR, Smolkin ME, Brenin DR, Chianese-Bullock KA et al (2017) A pilot study of the immunogenicity of a 9-peptide breast cancer vaccine plus poly-ICLC in early stage breast cancer. J Immunother Cancer 5:92","journal-title":"J Immunother Cancer"},{"key":"5274_CR14","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1038\/modpathol.2008.69","volume":"21","author":"AB Domfeh","year":"2008","unstructured":"Domfeh AB, Carley AL, Striebel JM, Karabakhtsian RG, Florea AV et al (2008) WT1 immunoreactivity in breast carcinoma: selective expression in pure and mixed mucinous subtypes. Mod Pathol 21:1217\u20131223","journal-title":"Mod Pathol"},{"key":"5274_CR15","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1158\/0008-5472.CAN-08-2926","volume":"69","author":"LM Ebert","year":"2009","unstructured":"Ebert LM, Liu YC, Clements CS, Robson NC, Jackson HM et al (2009) A long, naturally presented immunodominant epitope from NY-ESO-1 tumor antigen: implications for cancer vaccine design. Cancer Res 69:1046\u20131054","journal-title":"Cancer Res"},{"key":"5274_CR16","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.semcancer.2021.04.016","volume":"76","author":"C Fan","year":"2021","unstructured":"Fan C, Qu H, Wang X, Sobhani N, Wang L et al (2021) Cancer\/testis antigens: from serology to mRNA cancer vaccine. Semin Cancer Biol 76:218\u2013231","journal-title":"Semin Cancer Biol"},{"key":"5274_CR17","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1158\/0008-5472.CAN-13-2908","volume":"74","author":"J Fourcade","year":"2014","unstructured":"Fourcade J, Sun Z, Pagliano O, Chauvin JM, Sander C et al (2014) PD-1 and Tim-3 regulate the expansion of tumor antigen-specific CD8+ T cells induced by melanoma vaccines. Cancer Res 74:1045\u20131055","journal-title":"Cancer Res"},{"key":"5274_CR18","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1023\/A:1008255630202","volume":"8","author":"T Fujie","year":"1997","unstructured":"Fujie T, Mori M, Ueo H, Sugimachi K, Akiyoshi T (1997) Expression of MAGE and BAGE genes in Japanese breast cancers. Ann Oncol 8:369\u2013372","journal-title":"Ann Oncol"},{"key":"5274_CR19","doi-asserted-by":"publisher","first-page":"4922","DOI":"10.1158\/0008-5472.CAN-05-3840","volume":"66","author":"T Fukuyama","year":"2006","unstructured":"Fukuyama T, Hanagiri T, Takenoyama M, Ichiki Y, Mizukami M et al (2006) Identification of a new cancer\/germline gene, KK-LC-1, encoding an antigen recognized by autologous CTL induced on human lung adenocarcinoma. Cancer Res 66:4922\u20134928","journal-title":"Cancer Res"},{"issue":"3","key":"5274_CR20","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.3390\/ijms24031897","volume":"24","author":"D Hannani","year":"2023","unstructured":"Hannani D, Leplus E, Laurin D, Caulier B, Aspord C et al (2023) A new plasmacytoid dendritic cell-based vaccine in combination with anti-PD-1 expands the tumor-specific CD8+ T cells of lung cancer patients. Int J Mol Sci 24(3):1897","journal-title":"Int J Mol Sci"},{"key":"5274_CR21","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.1200\/JCO.19.00177","volume":"37","author":"AB Hont","year":"2019","unstructured":"Hont AB, Cruz CR, Ulrey R, O\u2019Brien B, Stanojevic M et al (2019) Immunotherapy of relapsed and refractory solid tumors with ex vivo expanded multi-tumor associated antigen specific cytotoxic T lymphocytes: a phase I study. J Clin Oncol 37:2349\u20132359","journal-title":"J Clin Oncol"},{"key":"5274_CR22","doi-asserted-by":"publisher","first-page":"175883592211071","DOI":"10.1177\/17588359221107113","volume":"14","author":"V Hoyos","year":"2022","unstructured":"Hoyos V, Vasileiou S, Kuvalekar M, Watanabe A, Tzannou I et al (2022) Multi-antigen-targeted T-cell therapy to treat patients with relapsed\/refractory breast cancer. Ther Adv Med Oncol 14:17588359221107112","journal-title":"Ther Adv Med Oncol"},{"key":"5274_CR23","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.canlet.2015.07.039","volume":"368","author":"L Hui","year":"2015","unstructured":"Hui L, Chen Y (2015) Tumor microenvironment: Sanctuary of the devil. Cancer Lett 368:7\u201313","journal-title":"Cancer Lett"},{"key":"5274_CR24","doi-asserted-by":"publisher","first-page":"5923","DOI":"10.21873\/anticanres.12937","volume":"38","author":"Y Kondo","year":"2018","unstructured":"Kondo Y, Fukuyama T, Yamamura R, Futawatari N, Ichiki Y et al (2018) Detection of KK-LC-1 protein, a cancer\/testis antigen, in patients with breast cancer. Anticancer Res 38:5923\u20135928","journal-title":"Anticancer Res"},{"key":"5274_CR25","first-page":"144","volume":"21","author":"EC LaVoy","year":"2015","unstructured":"LaVoy EC, Bollard CM, Hanley PJ, Blaney JW, O\u2019Connor DP et al (2015) A single bout of dynamic exercise enhances the expansion of MAGE-A4 and PRAME-specific cytotoxic T-cells from healthy adults. Exerc Immunol Rev 21:144\u2013153","journal-title":"Exerc Immunol Rev"},{"key":"5274_CR26","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1159\/000439535","volume":"89","author":"HJ Lee","year":"2015","unstructured":"Lee HJ, Kim JY, Song IH, Park IA, Yu JH et al (2015) Expression of NY-ESO-1 in triple-negative breast cancer is associated with tumor-infiltrating lymphocytes and a good prognosis. Oncology 89:337\u2013344","journal-title":"Oncology"},{"key":"5274_CR27","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.12207","author":"S Lei","year":"2020","unstructured":"Lei S, Zheng R, Zhang S, Wang S, Chen R et al (2020) Global patterns of breast cancer incidence and mortality: a population-based cancer registry data analysis from 2000 to 2020. Cancer Commun (london, England). https:\/\/doi.org\/10.1002\/cac2.12207","journal-title":"Cancer Commun (london, England)"},{"key":"5274_CR28","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1056\/NEJMoa2119662","volume":"386","author":"R Leidner","year":"2022","unstructured":"Leidner R, Sanjuan Silva N, Huang H, Sprott D, Zheng C et al (2022) Neoantigen T-cell receptor gene therapy in pancreatic cancer. N Engl J Med 386:2112\u20132119","journal-title":"N Engl J Med"},{"key":"5274_CR29","doi-asserted-by":"publisher","first-page":"8840","DOI":"10.1038\/ncomms9840","volume":"6","author":"KE Maxfield","year":"2015","unstructured":"Maxfield KE, Taus PJ, Corcoran K, Wooten J, Macion J et al (2015) Comprehensive functional characterization of cancer-testis antigens defines obligate participation in multiple hallmarks of cancer. Nat Commun 6:8840","journal-title":"Nat Commun"},{"key":"5274_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.960323","volume":"13","author":"Y Qi","year":"2022","unstructured":"Qi Y, Zhang W, Jiang R, Xu O, Kong X et al (2022) Efficacy and safety of PD-1 and PD-L1 inhibitors combined with chemotherapy in randomized clinical trials among triple-negative breast cancer. Front Pharmacol 13:960323","journal-title":"Front Pharmacol"},{"key":"5274_CR31","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1111\/his.13498","volume":"73","author":"A Raghavendra","year":"2018","unstructured":"Raghavendra A, Kalita-de Croft P, Vargas AC, Smart CE, Simpson PT et al (2018) Expression of MAGE-A and NY-ESO-1 cancer\/testis antigens is enriched in triple-negative invasive breast cancers. Histopathology 73:68\u201380","journal-title":"Histopathology"},{"key":"5274_CR32","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1097\/PAS.0000000000001264","volume":"43","author":"H Reis","year":"2019","unstructured":"Reis H, Serrette R, Posada J, Lu V, Chen YB et al (2019) PD-L1 expression in urothelial carcinoma with predominant or pure variant histology: concordance among 3 commonly used and commercially available antibodies. Am J Surg Pathol 43:920\u2013927","journal-title":"Am J Surg Pathol"},{"key":"5274_CR33","doi-asserted-by":"publisher","first-page":"5901","DOI":"10.1016\/j.vaccine.2014.09.002","volume":"32","author":"T Saito","year":"2014","unstructured":"Saito T, Wada H, Yamasaki M, Miyata H, Nishikawa H et al (2014) High expression of MAGE-A4 and MHC class I antigens in tumor cells and induction of MAGE-A4 immune responses are prognostic markers of CHP-MAGE-A4 cancer vaccine. Vaccine 32:5901\u20135907","journal-title":"Vaccine"},{"key":"5274_CR34","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1093\/annonc\/mdu450","volume":"26","author":"R Salgado","year":"2015","unstructured":"Salgado R, Denkert C, Demaria S, Sirtaine N, Klauschen F et al (2015) The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann Oncol 26:259\u2013271","journal-title":"Ann Oncol"},{"key":"5274_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2022.154299","volume":"241","author":"SHC See","year":"2023","unstructured":"See SHC, Smith SH, Finkelman BS, LaBoy C, Novo JE et al (2023) The role of PRAME and NY-ESO-1 as potential therapeutic and prognostic biomarkers in triple-negative breast carcinomas. Pathol Res Pract 241:154299","journal-title":"Pathol Res Pract"},{"key":"5274_CR36","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1038\/nrc1669","volume":"5","author":"AJ Simpson","year":"2005","unstructured":"Simpson AJ, Caballero OL, Jungbluth A, Chen YT, Old LJ (2005) Cancer\/testis antigens, gametogenesis and cancer. Nat Rev Cancer 5:615\u2013625","journal-title":"Nat Rev Cancer"},{"key":"5274_CR37","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.gene.2016.09.016","volume":"594","author":"Z Sun","year":"2016","unstructured":"Sun Z, Wu Z, Zhang F, Guo Q, Li L et al (2016) PRAME is critical for breast cancer growth and metastasis. Gene 594:160\u2013164","journal-title":"Gene"},{"key":"5274_CR38","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1001\/jama.2018.19323","volume":"321","author":"AG Waks","year":"2019","unstructured":"Waks AG, Winer EP (2019) Breast cancer treatment: a review. JAMA 321:288\u2013300","journal-title":"JAMA"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-023-05274-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-023-05274-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-023-05274-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T11:19:54Z","timestamp":1698319194000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-023-05274-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,23]]},"references-count":38,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["5274"],"URL":"https:\/\/doi.org\/10.1007\/s00432-023-05274-0","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,23]]},"assertion":[{"value":"18 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors declare no financial or non-financial competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All authors declare that this work has been carried out in accordance with The Code of Ethics of the World Medical Association (Declaration of Helsinki). The Medical Ethics Committee of Drum Tower Hospital Affiliated to Nanjing University Medical School approved the study\u2019s research protocol (2023-152-01). Informed consent and authorization were obtained from the patients for the use of their tumor tissues for research purposes.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}